Literature DB >> 21939667

Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury.

Ming Cai1, Zachary M Huttinger, Heng He, Weizhi Zhang, Feng Li, Lauren A Goodman, Debra G Wheeler, Lawrence J Druhan, Jay L Zweier, Karen M Dwyer, Guanglong He, Anthony J F d'Apice, Simon C Robson, Peter J Cowan, Richard J Gumina.   

Abstract

Modulation of purinergic signaling is critical to myocardial homeostasis. Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD-1; CD39) which converts the proinflammatory molecules ATP or ADP to AMP is a key regulator of purinergic modulation. However, the salutary effects of transgenic over expression of ENTPD-1 on myocardial response to ischemic injury have not been tested to date. Therefore we hypothesized that ENTPD-1 over expression affords myocardial protection from ischemia-reperfusion injury via specific cell signaling pathways. ENTPD-1 transgenic mice, which over express human ENTPDase-1, and wild-type (WT) littermates were subjected to either ex vivo or in vivo ischemia-reperfusion injury. Infarct size, inflammatory cell infiltrate and intracellular signaling molecule activation were evaluated. Infarct size was significantly reduced in ENTPD-1 versus WT hearts in both ex vivo and in vivo studies. Following ischemia-reperfusion injury, ENTPD-1 cardiac tissues demonstrated an increase in the phosphorylation of the cellular signaling molecule extracellular signal-regulated kinases 1/2 (ERK 1/2) and glycogen synthase kinase-3β (GSK-3β). Resistance to myocardial injury was abrogated by treatment with a non-selective adenosine receptor antagonist, 8-SPT or the more selective A(2B) adenosine receptor antagonist, MRS 1754, but not the A(1) selective antagonists, DPCPX. Additionally, treatment with the ERK 1/2 inhibitor PD98059 or the mitochondrial permeability transition pore opener, atractyloside, abrogated the cardiac protection provided by ENTPDase-1 expression. These results suggest that transgenic ENTPDase-1 expression preferentially conveys myocardial protection from ischemic injury via adenosine A(2B) receptor engagement and associated phosphorylation of the cellular protective signaling molecules, Akt, ERK 1/2 and GSK-3β that prevents detrimental opening of the mitochondrial permeability transition pore. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21939667      PMCID: PMC3245748          DOI: 10.1016/j.yjmcc.2011.09.003

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  56 in total

Review 1.  Adenosine and its receptors in the heart: regulation, retaliation and adaptation.

Authors:  John P Headrick; Jason N Peart; Melissa E Reichelt; Luke J Haseler
Journal:  Biochim Biophys Acta       Date:  2010-11-19

2.  Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade.

Authors:  Sebastian Philipp; Xi-Ming Yang; Lin Cui; Amanda M Davis; James M Downey; Michael V Cohen
Journal:  Cardiovasc Res       Date:  2006-02-23       Impact factor: 10.787

3.  Involvement of caveolin in ligand-induced recruitment and internalization of A(1) adenosine receptor and adenosine deaminase in an epithelial cell line.

Authors:  S Ginés; F Ciruela; J Burgueño; V Casadó; E I Canela; J Mallol; C Lluís; R Franco
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

4.  Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection.

Authors:  R M Fryer; P F Pratt; A K Hsu; G J Gross
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

5.  CD39 as a caveolar-associated ectonucleotidase.

Authors:  A Kittel; E Kaczmarek; J Sevigny; K Lengyel; E Csizmadia; S C Robson
Journal:  Biochem Biophys Res Commun       Date:  1999-09-07       Impact factor: 3.575

6.  Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia.

Authors:  Almut Grenz; Hua Zhang; Tobias Eckle; Michel Mittelbronn; Manfred Wehrmann; Christoph Köhle; Doris Kloor; Linda F Thompson; Hartmut Osswald; Holger K Eltzschig
Journal:  J Am Soc Nephrol       Date:  2007-01-31       Impact factor: 10.121

Review 7.  Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.

Authors:  Simon C Robson; Yan Wu; Xiaofeng Sun; Christoph Knosalla; Karen Dwyer; Keiichi Enjyoji
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

8.  A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. cross-talk between cyclic AMP and protein kinase c pathways.

Authors:  Z Gao; T Chen; M J Weber; J Linden
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

9.  Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor.

Authors:  Jason E Maas; Tina C Wan; Robert A Figler; Garrett J Gross; John A Auchampach
Journal:  J Mol Cell Cardiol       Date:  2010-08-24       Impact factor: 5.000

10.  Stimulation of adenosine A2b receptors blocks apoptosis in the non-infarcted myocardium even when administered after the onset of infarction.

Authors:  Gregor Simonis; Stephan Wiedemann; Dirk Joachim; Christof Weinbrenner; Rainer Marquetant; Ruth H Strasser
Journal:  Mol Cell Biochem       Date:  2009-03-20       Impact factor: 3.396

View more
  23 in total

1.  Transgenic swine: expression of human CD39 protects against myocardial injury.

Authors:  Debra G Wheeler; Matthew E Joseph; Shouvik D Mahamud; William L Aurand; Peter J Mohler; Vincent J Pompili; Karen M Dwyer; Mark B Nottle; Sharon J Harrison; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  J Mol Cell Cardiol       Date:  2012-01-12       Impact factor: 5.000

2.  Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice.

Authors:  Zachary M Huttinger; Michael W Milks; Michael S Nickoli; William L Aurand; Lawrence C Long; Debra G Wheeler; Karen M Dwyer; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  Am J Pathol       Date:  2012-05-18       Impact factor: 4.307

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 4.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

5.  Hydrolysis of extracellular ATP by ectonucleoside triphosphate diphosphohydrolase (ENTPD) establishes the set point for fibrotic activity of cardiac fibroblasts.

Authors:  David Lu; Paul A Insel
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

6.  Ectonucleotidase CD39-driven control of postinfarction myocardial repair and rupture.

Authors:  Nadia R Sutton; Takanori Hayasaki; Matthew C Hyman; Anuli C Anyanwu; Hui Liao; Danica Petrovic-Djergovic; Linda Badri; Amy E Baek; Natalie Walker; Keigo Fukase; Yogendra Kanthi; Scott H Visovatti; Ellen L Horste; Jessica J Ray; Sascha N Goonewardena; David J Pinsky
Journal:  JCI Insight       Date:  2017-01-12

7.  Kcnj11 Ablation Is Associated With Increased Nitro-Oxidative Stress During Ischemia-Reperfusion Injury: Implications for Human Ischemic Cardiomyopathy.

Authors:  Bo Zhang; Tatiana Novitskaya; Debra G Wheeler; Zhaobin Xu; Elena Chepurko; Ryan Huttinger; Heng He; Saradhadevi Varadharaj; Jay L Zweier; Yanna Song; Meng Xu; Frank E Harrell; Yan Ru Su; Tarek Absi; Mark J Kohr; Mark T Ziolo; Dan M Roden; Christian M Shaffer; Cristi L Galindo; Quinn S Wells; Richard J Gumina
Journal:  Circ Heart Fail       Date:  2017-02       Impact factor: 8.790

8.  Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?

Authors:  Jan David Hohmann; Xiaowei Wang; Stefanie Krajewski; Carly Selan; Carolyn A Haller; Andreas Straub; Elliot L Chaikof; Harshal H Nandurkar; Christoph E Hagemeyer; Karlheinz Peter
Journal:  Blood       Date:  2013-02-04       Impact factor: 22.113

9.  Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.

Authors:  Douglas Moeckel; Soon Soeg Jeong; Xiaofeng Sun; M Johan Broekman; Annie Nguyen; Joan H F Drosopoulos; Aaron J Marcus; Simon C Robson; Ridong Chen; Dana Abendschein
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956

Review 10.  CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Authors:  Bellamkonda K Kishore; Simon C Robson; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2018-01-13       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.